Floatz logo

Irinotecan

Basal Cell Carcinoma

Genentech, Inc.Small moleculePhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Basal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Gdc-0449
Genentech, Inc.
Phase 2B
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC

View all 32 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →